The Han:SPRD Rat: A Preclinical Model of Polycystic Kidney Disease-Reference-Cited by-同舟云学术

The Han:SPRD Rat: A Preclinical Model of Polycystic Kidney Disease

Published:2024-02-03 Issue:2 Volume:12 Page:362
ISSN:2227-9059
Container-title:Biomedicines
language:en
Short-container-title:Biomedicines

Author:

Kofotolios Ioannis¹²^ORCID,Bonios Michael J.³,Adamopoulos Markos²^ORCID,Mourouzis Iordanis⁴,Filippatos Gerasimos⁵,Boletis John N.¹,Marinaki Smaragdi¹,Mavroidis Manolis²^ORCID

Affiliation:

1. Clinic of Nephrology and Renal Tranplantation, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

2. Center of Basic Research, Biomedical Research Foundation, Academy of Athens, 11527 Athens, Greece

3. Heart Failure and Transplant Unit, Onassis Cardiac Surgery Center, 17674 Athens, Greece

4. Department of Pharmacology, National and Kapodistrian University of Athens, 11527 Athens, Greece

5. Department of Cardiology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece

Abstract

Autosomal Dominant Polycystic Kidney Disease (ADPKD) stands as the most prevalent hereditary renal disorder in humans, ultimately culminating in end-stage kidney disease. Animal models carrying mutations associated with polycystic kidney disease have played an important role in the advancement of ADPKD research. The Han:SPRD rat model, carrying an R823W mutation in the Anks6 gene, is characterized by cyst formation and kidney enlargement. The mutated protein, named Samcystin, is localized in cilia of tubular epithelial cells and seems to be involved in cystogenesis. The homozygous Anks6 mutation leads to end-stage renal disease and death, making it a critical factor in kidney development and function. This review explores the utility of the Han:SPRD rat model, highlighting its phenotypic similarity to human ADPKD. Specifically, we discuss its role in preclinical trials and its importance for investigating the pathogenesis of the disease and developing new therapeutic approaches.

Funder

Onassis Foundation

Publisher

MDPI AG

Link

https://www.mdpi.com/2227-9059/12/2/362/pdf

Reference89 articles.

1. An approach to cystic kidney diseases: The clinician’s view;Kurschat;Nat. Rev. Nephrol.,2014

2. Cystic Kidney Disease: A Primer;Cramer;Adv. Chronic Kidney Dis.,2015

3. Rohatgi, R. (2023, January 31). Extra-Renal Manifestations 5. Nephronophthisis (NPHP)-Medullary Cystic Kidney Disease (MCKD). Available online: http://pkdb.mayo.edu,.

4. Epidemiology of Adult Polycystic Kidney Disease, Olmsted County, Minnesota: 1935–1980;Iglesias;Am. J. Kidney Dis.,1983

5. Solazzo, A., Testa, F., Giovanella, S., Busutti, M., Furci, L., Carrera, P., Ferrari, M., Ligabue, G., Mori, G., and Leonelli, M. (2018). The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PloS ONE, 13.